Heart failure pharmacogenetics: Past, present, and future

被引：8
作者：
Davis H.M. [1 ]
Johnson J.A. [1 ,2 ,3 ]
机构：
[1] Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville
[2] Department of Medicine, College of Medicine, University of Florida, Gainesville
[3] Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32610
来源：
Current Cardiology Reports | 2011年 / 13卷 / 3期
关键词：
β; blocker; ACE inhibitor; Heart failure; Left ventricular ejection fraction; Mortality; Pharmacogenetics;
D O I：
10.1007/s11886-011-0181-6
中图分类号：
学科分类号：
摘要：
Heart failure is an increasingly common disease associated with significant morbidity and mortality in the aging population. Recent advances in heart failure pharmacotherapy have established several agents as beneficial to disease progression and outcomes. However, current consensus guideline-recommended pharmacotherapy may not represent an optimal treatment strategy in all heart failure patients. Specifically, individuals with genetic variation in regions central to mediation of beneficial response to standard heart failure agents may not receive optimal benefit from these drugs. Additionally, targeted approaches in phase 3 clinical trials that select patients for inclusion based on the genotype most likely to respond might advance the currently stalled drug development pipeline in heart failure. This article reviews the literature in heart failure pharmacogenetics to date, opportunities for discovery in recent and upcoming clinical trials, as well as future directions in this field. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：175 / 184
页数：9
相关论文
共 45 条
  • [1] Hunt S.A., Abraham W.T., Chin M.H., Et al., 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation, J Am Coll Cardiol, 53, (2009)
  • [2] Hjalmarson A., Goldstein S., Fagerberg B., Wedel H., Waagstein F., Kjekshus J., Wikstrand J., El A.D., Vitovec J., Aldershvile J., Halinen M., Dietz R., Neuhaus K.-L., Janosi A., Thorgeirsson G., Dunselman P.H.J.M., Gullestad L., Kuch J., Herlitz J., Riekenbacher P., Ball S., Gottlieb S., Deedwania P., Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The metoprolol CR/XL randomized intervention trial in congestive hear
  • [3] Poole-Wilson P.A., Swedberg K., Cleland J.G.F., Di L.A., Hanrath P., Komajda M., Lubsen J., Lutiger B., Metra M., Remme W.J., Torp-Pedersen C., Scherhag A., Skene A., Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial, Lancet, 362, 9377, pp. 7-13, (2003)
  • [4] The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial, Lancet, 353, pp. 9-13, (1999)
  • [5] Triposkiadis F., Karayannis G., Giamouzis G., Skoularigis J., Louridas G., Butler J., The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications, J Am Coll Cardiol, 54, pp. 1747-1762, (2009)
  • [6] Xiao R.P., Beta-adrenergic signaling in the heart: Dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins, Sci STKE, 2001, (2001)
  • [7] Mason D.A., Moore J.D., Green S.A., Liggett S.B., A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor, J Biol Chem, 274, pp. 12670-12674, (1999)
  • [8] Rathz D.A., Gregory K.N., Fang Y., Brown K.M., Liggett S.B., Hierarchy of polymorphic variation and desensitization permutations relative to beta<sub>1</sub>- and beta<sub>2</sub>-adrenergic receptor signaling, Journal of Biological Chemistry, 278, 12, pp. 10784-10789, (2003)
  • [9] Perez J.M., Rathz D.A., Petrashevskaya N.N., Hahn H.S., Wagoner L.E., Schwartz A., Dorn II G.W., Liggett S.B., Beta<sub>1</sub>-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure, Nature Medicine, 9, 10, pp. 1300-1305, (2003)
  • [10] Chen L., Meyers D., Javorsky G., Burstow D., Lolekha P., Lucas M., Semmler A.B.T., Savarimuthu S.M., Fong K.M., Yang I.A., Atherton J., Galbraith A.J., Parsonage W.A., Molenaar P., Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol, Pharmacogenetics and Genomics, 17, 11, pp. 941-949, (2007)
12345